AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Home
/
update
/
details

Myriad Genetics and jscreen Announce Strategic Partnership to Expand Access to Preventative Genetic Testing

NextEdge Admin

17 Oct 2024

2 min 17 sec

Myriad Genetics a leader in genetic testing and precision medicine, announced a strategic partnership with jscreen™, a national organization focused on providing education and access to preventative genetic testing, particularly for high-risk populations.

This collaboration integrates Myriad's renowned hereditary cancer and reproductive genetics products, including MyRisk® with RiskScore® and the Foresight® Carrier Screen, with jscreen's robust education and genetic care navigation programs. Together, they aim to reach hundreds of thousands of high-risk adults across the U.S. through outreach, educational initiatives, and in-person screenings.

"BRCA mutations raise the risk for several cancers, including breast and ovarian cancer," noted Melissa Gonzales, President of Women's Health at Myriad Genetics. "Our partnership with jscreen aligns with our shared commitment to improving patient care by ensuring equitable access to high-quality genetic testing. This collaboration will help individuals, particularly those of Jewish descent, better understand their hereditary risks and make informed healthcare decisions."

Matt Goldstein, MD, PhD, CEO of jscreen, expressed gratitude for the partnership. "Myriad’s excellence in quality and customer service reflects the standard we’ve provided for over a decade. This collaboration enhances our ability to expand access to life-saving preventative genetic care," he said. "As a pioneer in telegenetics, jscreen has long focused on raising awareness about genetic testing and increasing access to carrier screening and cancer risk assessments."

This partnership is poised to make preventive genetic testing more accessible and impactful nationwide.